MDVerse integrates software, analytics, and generative AI to deliver personalized, precision regenerative medicine therapies on demand. The platform connects drug creators, CDMOs, academia, and clinical sites across the advanced therapy medicinal product (ATMP) ecosystem. This integration ensures the efficient supply chain management necessary for scaling cell and gene therapy clinical trials and commercialization.
Funding
$380K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development and delivery of precision regenerative medicine is hindered by inadequate supply confidence in cell and gene therapy trials. This challenge prevents healthcare professionals from consistently providing effective treatments for various medical conditions.
Solution
MDVerse integrates generative AI, advanced analytics, and tailor-made therapeutics to streamline the development and delivery of precision regenerative medicine. The company's platform addresses the supply chain challenges in cell and gene therapy by linking drug creators, pharma companies, CDMOs, academia, clinical sites, and the materials ecosystem. By integrating these elements, MDVerse aims to ensure that precision therapeutics are delivered within the entire ATMP (Advanced Therapy Medicinal Product) ecosystem, bridging the gap between research and clinical application. The platform facilitates iterative formulations, manufacturing, and clinical trials, with patient inclusion at every step.
Target Audience
The primary target audience includes pharmaceutical companies, contract development and manufacturing organizations (CDMOs), academic research institutions, and clinical sites involved in cell and gene therapy and regenerative medicine.
Features
- Next-generation software platform for managing the ATMP ecosystem
- AI/ML-driven analytics for optimizing therapeutic development
- Integration of drug creators, pharma, CDMOs, academia, and clinical sites
- Support for cell and gene therapy, stem cells, and tissue engineering
- Data exchange capabilities across the entire ecosystem